Chemistry:2CBCB-NBOMe

From HandWiki

2CBCB-NBOMe, or NBOMe-TCB-2, is a serotonin receptor modulator and cyclized phenethylamine.[1][2] It is the NBOMe derivative of the psychedelic drug TCB-2 (2C-BCB).[1][2]

Interactions

Pharmacology

Pharmacodynamics

2CBCB-NBOMe acts as a potent and selective agonist of the serotonin 5-HT2A and 5-HT2C receptors, with an affinity (Ki) of 0.27 nM at the human serotonin 5-HT2A receptor, similar to that of other drugs such as TCB-2, 25I-NBOMe, and Bromo-DragonFLY.[1][2]

History

2CB2CB-NBOMe was first described in the scientific literature by the lab of David E. Nichols and colleagues in 2007.[1][2] It was part of an ongoing research program focused on mapping of the specific amino acid residues responsible for ligand binding to the serotonin 5-HT2A receptor.[1][2]

Society and culture

Canada

2CBCB-NBOMe is not a controlled substance in Canada as of 2025.[3]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[4]


United States

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.[5]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 (in de) Phenethylamine: von der Struktur zur Funktion. Nachtschatten-Science (1st ed.). Solothurn: Nachtschatten-Verlag. 2013. pp. 861. ISBN 978-3-03788-700-4. OCLC 858805226. https://books.google.com/books?id=-Us1kgEACAAJ. 
  2. 2.0 2.1 2.2 2.3 2.4 Braden MR (2007). Towards a biophysical understanding of hallucinogen action (Ph.D.). Purdue University. ProQuest 304838368.
  3. "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 
  4. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014" (in en). http://www.legislation.gov.uk/uksi/2014/1106/made. 
  5. "Regulated Drugs Rule". Vermont Department of Health. http://healthvermont.gov/regs/documents/regulated_drugs_rule.pdf.